Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$437.00
|
|
Provider: Thomson Reuters StreetEvents
|
$75.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
SBI Holdings Inc Announces Changes in Subsidiary
SBI Holdings Inc announced that its subsidiary SBI Biotech Co., Ltd., which engages in the research and development of medicals, has fully acquired the Company's United States-based subsidiary Quark Pharmaceuticals, Inc., which engages in the research and development of siRNA medicals. Now Quark Pharmaceuticals is a subsidiary of SBI Biotech.
Latest Developments for SBI Holdings Inc
- SBI Holdings Inc Acquires Shares of Hyundai Swiss Savings Bank
- SBI Holdings Inc Announces Changes in Subsidiary
- SBI Holdings Inc to Acquire Shares of photonamic GmbH & Co. KG; Receives Approval to Establish Fund Management Company
- SBI Holdings Inc Lowers Consolidated Mid-year and Full-year Outlook for FY Ending March 31, 2013
Latest Key Developments in Investment
- Share this
- Link this
- Digg this
Follow Reuters